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Nowadays, psychiatrists have a wide range of treatment
choices to treat acute mania. Introduction of atypical
antipsychotics in the last decade has increased the range
of available treatments. A good number of double-blind
randomized clinical trials have supported the efficacy of
several atypicals, (aripiprazole, olanzapine, quetiapine,
risperidone, ziprasidone) both as monotherapy and in
combination with lithium or valproate. I.m. formulations
of aripiprazole and olanzapine have also shown efficacy
in agitated patients suffering acute mania. More
recently, asenapine (both as monotherapy or combina-
tion) and paliperidone (only monotherapy so far) have
shown positive results and may deserve a second-line
option according to the most recent clinical guidelines.
Atypicals are recommended over typical antipsychotics
due to a better short-term side-effect profile. Although
not yet proved in meta-analysis, several trials show that
atypicals also have a lower risk of switch to depression.
More “classical” mood-stabilizers, such as lithium,
valproate, and carbamazepine also share evidence-based
antimanic properties. However, some data show lithium
being slightly slower in his action, and carbamazepine not
being advisable in combination (negative results with ris-
peridone and olanzapine, and not tested with other atypi-
cals). Clinical guidelines usually recommend monotherapy
with an antimanic agent to treat mild or moderate mania,
and combination treatment (usually with lithium or
valproate plus an atypical antipsychotic) for more severe
mania. However, combination treatment is usually the rule
in clinical practice, especially when the patient is already
taking a mood-stabilizer with antimanic action, taking for
granted adherence has been demonstrated. Pros and cons
of these different approaches will be discussed, as well as
differences among antimanic treatment combinations. The
use of benzodiazepines in the short-term, for managament
of insomnia and psychomotor agitation is also a
recommended strategy in most guidelines. For treatment
resistant mania, there is some evidence supporting the use
of clozapine, and ECT may also be a good option. Novel
treatments, such as tamoxifen, with four small positive
randomized clinical trials, suggest new mechanisms of
action that could be further understood in next years.
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